Organon & Company

OGN

Equity

ISIN US68622V1061 / Valor 111523364

New York Stock Exchange, Inc (2024-12-20)

USD 14.58+0.97%

Organon & Company
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Organon & Company is a global healthcare company with a diverse portfolio of therapies and products focused on women's health, biosimilars, and established brands covering various conditions and diseases. Their established brands include treatments for cardiovascular disease, respiratory conditions, dermatology, central nervous system disorders, bone health, immunology, non-opioid pain management, menopause, and more. With a portfolio of over 60 medicines and products, Organon operates in more than 140 markets worldwide, offering important therapies in areas such as reproductive health, heart disease, oncology, immunology, dermatology, allergy, and asthma.

Summarized from source with an LLMView SourceSector: Industrials

Revenue Growth

Organon & Company reported revenue of $1.6 billion for the second quarter of 2024, reflecting a 2% increase when adjusted for foreign exchange (ex-FX). This growth was driven by strong performance in key franchises, despite some offsetting factors in other areas.

Earnings Per Share

For Q2 2024, Organon & Company achieved a diluted earnings per share (EPS) of $0.75. On an adjusted basis, the diluted EPS was $1.12, showcasing the company's ability to maintain profitability amidst varying market conditions.

Adjusted EBITDA

Organon & Company reported an adjusted EBITDA of $513 million for the second quarter of 2024. This figure includes $15 million related to in-process research and development (IPR&D) and milestone payments, indicating ongoing investment in future growth opportunities.

Women's Health Segment

The Women's Health segment saw a 3% growth ex-FX in Q2 2024, with strong performances from products like Nexplanon and Marvelon/Mercilon. However, this was partially offset by weaker performance in the Fertility and NuvaRing product lines.

Geographic Performance

In Q2 2024, Organon & Company experienced varied performance across different regions. The United States saw a 5% increase in revenue, while Europe and Canada experienced a slight decline of 1% ex-FX. China faced a 4% decline ex-FX, reflecting regional market challenges.

Summarized from source with an LLMView Source

Key figures

11.0%1Y

-50.3%3Y

%5Y

Performance

38.9%1Y

36.8%3Y

37.7%5Y

Volatility